Nasdaq · Common stock
BlossomHill Therapeutics (BLSM)
$16.39 +$1.76 (+12.03%)
- Day’s range
- $14.53–$16.82
- Volume
- 204,368
BLSM price history
BLSM closed at $16.39 on Oct. 26, 2026. Over the past year, its daily close ranged from $13.94 on Oct. 16, 2026 to $26.82 on Sept. 17, 2026.
Data table: BLSM daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $16.39 |
| Oct. 23, 2026 | $14.63 |
| Oct. 22, 2026 | $15.81 |
| Oct. 21, 2026 | $15.60 |
| Oct. 20, 2026 | $14.40 |
| Oct. 19, 2026 | $14.16 |
| Oct. 16, 2026 | $13.94 |
| Oct. 15, 2026 | $14.98 |
| Oct. 14, 2026 | $15.26 |
| Oct. 13, 2026 | $15.48 |
| Oct. 12, 2026 | $17.27 |
| Oct. 9, 2026 | $17.48 |
| Oct. 8, 2026 | $16.88 |
| Oct. 7, 2026 | $16.61 |
| Oct. 6, 2026 | $17.29 |
| Oct. 5, 2026 | $19.94 |
| Oct. 2, 2026 | $19.69 |
| Oct. 1, 2026 | $18.59 |
| Sept. 30, 2026 | $18.64 |
| Sept. 29, 2026 | $21.37 |
| Sept. 28, 2026 | $21.34 |
| Sept. 25, 2026 | $19.75 |
| Sept. 24, 2026 | $20.47 |
| Sept. 23, 2026 | $22.34 |
| Sept. 22, 2026 | $25.25 |
| Sept. 21, 2026 | $26.80 |
| Sept. 18, 2026 | $25.74 |
| Sept. 17, 2026 | $26.82 |
| Sept. 16, 2026 | $26.25 |
| Sept. 15, 2026 | $22.17 |
| Sept. 14, 2026 | $21.74 |
| Sept. 11, 2026 | $20.86 |
| Sept. 10, 2026 | $21.51 |
| Sept. 9, 2026 | $22.00 |
| Sept. 8, 2026 | $22.93 |
| Sept. 4, 2026 | $22.01 |
| Sept. 3, 2026 | $20.02 |
| Sept. 2, 2026 | $19.38 |
| Sept. 1, 2026 | $18.99 |
| Aug. 31, 2026 | $18.30 |
| Aug. 28, 2026 | $19.56 |
| Aug. 27, 2026 | $19.80 |
| Aug. 26, 2026 | $18.46 |
| Aug. 25, 2026 | $18.42 |
| Aug. 24, 2026 | $16.03 |
| Aug. 21, 2026 | $16.38 |
| Aug. 20, 2026 | $15.80 |
| Aug. 19, 2026 | $16.17 |
| Aug. 18, 2026 | $16.10 |
| Aug. 17, 2026 | $16.38 |
| Aug. 14, 2026 | $16.18 |
| Aug. 13, 2026 | $16.35 |
| Aug. 12, 2026 | $16.24 |
| Aug. 11, 2026 | $16.52 |
| Aug. 10, 2026 | $15.99 |
| Aug. 7, 2026 | $16.00 |
Key figures
- Average daily volume
- 235,709Past 3 months
- Market value
- $521.0M
- Dividend yield
- —
Price change
- 1 month
- −17.01%
What Wall Street says about BLSM
In the past 90 days, Wall Street firms published 7 rating or price-target actions on BLSM: 5 new ratings and 2 raised price targets.
| Action | Rating | |||
|---|---|---|---|---|
| Guggenheim | Raises target | Buy | $30 to $40 | |
| Leerink Partners | Raises target | Outperform | $36 to $40 | |
| Guggenheim | Initiates coverage | Buy | $30 | |
| HC Wainwright & Co. | Initiates coverage | Buy | $35 | |
| JP Morgan | Initiates coverage | Overweight | $28 | |
| Leerink Partners | Initiates coverage | Outperform | $36 | |
| LifeSci Capital | Initiates coverage | Outperform | $32 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
- Headquarters
- San Diego, Calif.
- Employees
- 69
- Listed
- Aug. 7, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about BLSM is on the site yet.